Bienvenido a EMEI

Esta web ha sido acreditada por distintos organismos y fundaciones. Dicha acreditación sirve como garantía de que este sitio web, en la fecha de su certificación, cumple con unos requisitos mínimos que garantizan la fiabilidad y credibilidad de la información científica, médica y de salud que muestra.

EMEI- Últimos artículos científicos publicados:

• Vitamin D deficiency is associated with severity of liver disease in HIV/HCV coinfected patients. -

  Vitamin D deficiency is associated with severity of liver disease in HIV/HCV coinfected patients.

  J Infect. 2013 Oct 31;

  Authors: Guzmán-Fulgencio M, García-Álvarez M, Berenguer J, Jiménez-Sousa MA, Cosín J, Pineda-Tenor D, Carrero A, Aldámiz T, Alvarez E, López JC, Resino S

  Abstract
  OBJECTIVE: To study the association of plasma 25-hydroxy vitamin D (25(OH)D) levels in HIV/HCV coinfected patients with severity of liver disease and virological response to hepatitis C virus (HCV) therapy with pegylated-interferon-alpha plus ribavirin (pegIFNα/RBV).
  METHODS: A cross-sectional study in 174 HIV/HCV coinfected patients that underwent a liver biopsy previously to start HCV therapy and a retrospective study of 125 of them. Plasma 25(OH)D levels were quantified by enzyme immunoassay. Liver biopsies were evaluated by METAVIR score. A sustained virological response (SVR) was defined as an undetectable serum HCV viral load (<10 IU/mL) up through 24 weeks after the end of HCV treatment.
  RESULTS: The median of plasma 25(OH)D level was 48 nmol/L (p25th: 32.5; p75th: 56.1) and 27 (15.5%) had 25(OH)D deficiency (<25 nmol/L). The percentage of 25(OH)D deficiency was higher in patients with significant fibrosis (F≥2) (92.6% vs. 57.1%; p=0.010) and moderate necroinflammatory activity grade (A≥2) (85.2% vs. 60%; p=0.043). However, adjusted logistic regression analyses showed that 25(OH)D deficiency was only associated with severity of liver disease [F≥2 (OR=8.47 (95% of confidence interval (CI)=1.88; 38.3); p=0.005) and A≥2 (OR=3.25 (95%CI=1.06; 10.1); p=0.040)]. Moreover, any significant relationship was found between 25(OH)D deficiency and SVR after HCV therapy.
  CONCLUSION: Plasma 25(OH)D deficiency was associated with liver disease severity in HIV/HCV coinfected patients, but it was not associated with HCV treatment failure.
  

  PMID: 24184809 [PubMed - as supplied by publisher]

• ACSM4 polymorphisms are associated with rapid AIDS progression in human immunodeficiency virus infected patients. -

  Related Articles

  ACSM4 polymorphisms are associated with rapid AIDS progression in human immunodeficiency virus infected patients.

  J Acquir Immune Defic Syndr. 2013 Aug 26;

  Authors: Guzmán-Fulgencio M, Jiménez JL, Jiménez-Sousa MA, Bellón JM, García-Álvarez M, Soriano V, Gijón-Vidaurreta P, Bernal-Morell E, Viciana P, Muñoz-Fernández MA, Resino S

  Abstract
  Our aim was to explore the association among ACSM4 and PECI polymorphisms and AIDS progression in 454 HIV infected patients never treated with antiretroviral drugs (146 long term non-progressors, 228 moderate progressors, and 80 rapid progressors). For ACSM4 polymorphisms, rs7137120 AA/AG and rs7961991 CC/CT genotypes had higher odds of having a rapid AIDS progression (odds ratio (OR)=3.21 (95% of confidence interval (95%CI)=1.26-8.16); p=0.014) and OR=3.60 (95%CI=1.38-9.36); p=0.009), respectively). Additionally, the ACSM4 haplotype integrated for both rs7961991 A and rs7137120 C alleles had higher odds of having a rapid AIDS progression (OR=2.85 (95%CI=1.28-6.25), p=0.010). For PECI polymorphisms, no significant associations were found. In conclusion, ACSM4 polymorphisms might play a significant role in AIDS progression.
  

  PMID: 23982661 [PubMed - as supplied by publisher]

• HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy. -

  Related Articles

  HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy.

  AIDS. 2013 May 15;27(8):1231-8

  Authors: Guzmán-Fulgencio M, Berenguer J, Rallón N, Fernández-Rodríguez A, Miralles P, Soriano V, Jiménez-Sousa MA, Cosín J, Medrano J, García-Álvarez M, López JC, Benito JM, Resino S

  Abstract
  OBJECTIVES: To analyze whether human leukocyte antigen (HLA)-E allelic variants are associated with and may predict response to peg-interferon (IFN) alpha and ribavirin treatment in HIV/hepatitis C virus (HCV)-coinfected patients.
  DESIGN: Retrospective follow-up study.
  METHODS: We studied 321 naive patients who started HCV treatment. HLA-E genotyping was performed by restriction fragment length polymorphism. A sustained virological response (SVR) was defined as undetectable plasma HCV-RNA up through 24 weeks after the end of HCV treatment.
  RESULTS: The HLA-E*0101 allele increased the odds of achieving SVR for all patients [adjusted odds ratio (aOR) = 2.03 (95% confidence interval, 95% CI = 1.35-3.06); P = 0.001], for HCV genotype (GT) 1/4 patients (aOR = 1.62 (95% CI = 1.03-2.54), P = 0.035), and for GT2/3 patients [aOR = 9.87 (95% CI = 2.47-31.89), P = 0.001]. For decision tree analysis, the SVR rate increased from 0 to 82.6% and then to 92.5% in GT2/3 patients when the count of HLA-E*0101 alleles increased. In GT1/4 patients with rs8099917 TT genotype, the SVR rate increased from 33.3 to 54.8% and then to 61.8% when the count of HLA-E*0101 alleles increased. In GT1/4 patients with rs8099917 GT/GG genotype, the SVR rate increased from 15.4 to 22% and then to 44% when the count of HLA-E*0101 alleles increased. The overall percentage of patients correctly classified was 73.2% and the area under the receiver operating characteristic curve (AUROC) was 0.803 ± 0.024.
  CONCLUSION: The HLA-E*0101 allele was associated with increased odds of HCV clearance and could help to predict SVR among HIV/HCV-coinfected patients on HCV therapy. This would be helpful to avoid treatment in those less likely to respond to pegylated-interferon-alpha and ribavirin treatment.
  

  PMID: 23811951 [PubMed - in process]

• Prediction of hepatic fibrosis in patients coinfected with human immunodeficiency virus and hepatitis C virus based on genetic markers. -

  Related Articles

  Prediction of hepatic fibrosis in patients coinfected with human immunodeficiency virus and hepatitis C virus based on genetic markers.

  J Acquir Immune Defic Syndr. 2013 Jun 21;

  Authors: Fernández-Rodríguez A, Berenguer J, Jiménez-Sousa MA, Guzmán-Fulgencio M, Micheloud D, Miralles P, López JC, Bellón JM, Aldamiz-Echevarria T, García-Broncano P, Carrero A, Alvarez E, Resino S

  Abstract
  OBJECTIVE:: To assess the ability of the cirrhosis risk score (CRS) to predict liver fibrosis progression in HIV/HCV coinfected patients.
  DESIGN:: Retrospective follow-up study.
  METHODS:: Based on a minimum follow-up time of 10 years with HCV infection, 190 HIV/HCV coinfected patients were classified according to their METAVIR score: i) 25 non-progressor patients who did not develop fibrosis (F0); and ii) 165 progressor patients who developed fibrosis (F≥1). Seven polymorphisms of CRS signature and IL28B genotype were performed using the GoldenGate® assay. The CRS signature was calculated by Naïve Bayes formula as previously described.
  RESULTS:: Non-progressors had CRS values significantly lower than progressors (0.61 versus 0.67; p=0.043). Among the progressors, we observed similar CRS values through all the fibrosis stages (F1/F2/F3/F4). The percentage of patients with CRS>0.70 (high-risk of developing fibrosis) was higher in progressors than in non-progressors; but the percentages with values between 0.50-0.70 (intermediate risk) and <0.50 (low risk) were quite similar for each of the fibrosis stages (p=0.047). The area under the receiver operating characteristic curve (AUROC) of CRS for discriminating non-progressor versus progressor was 0.625 (p=0.043). When clinical variables were considered (age at HCV infection, IDU, gender, IL28B and HCV genotype), the AUROC of CRS improved up to 0.739 (p<0.001).
  CONCLUSION:: CRS itself seems not to be a good marker for identifying HIV/HCV coinfected patients who are at high risk of developing liver fibrosis. However, CRS score coupled with clinical factors might help to distinguish between non-progressors and progressors patients.
  

  PMID: 23797694 [PubMed - as supplied by publisher]

• European mitochondrial haplogroups are associated with CD4+ T cell recovery in HIV-infected patients on combination antiretroviral therapy. -

  Related Articles

  European mitochondrial haplogroups are associated with CD4+ T cell recovery in HIV-infected patients on combination antiretroviral therapy.

  J Antimicrob Chemother. 2013 Oct;68(10):2349-57

  Authors: Guzmán-Fulgencio M, Berenguer J, Micheloud D, Fernández-Rodríguez A, García-Álvarez M, Jiménez-Sousa MA, Bellón JM, Campos Y, Cosín J, Aldámiz-Echevarría T, Catalán P, López JC, Resino S

  Abstract
  BACKGROUND: There is substantial interindividual variability in the rate and extent of CD4+ T cell recovery after starting combination antiretroviral therapy (cART). The aim of our study was to determine whether mitochondrial DNA (mtDNA) haplogroups are associated with recovery of CD4+ in HIV-infected patients on cART.
  METHODS: We carried out a retrospective study on 275 cART-naive patients with CD4+ counts <350 cells/mm(3), who were followed-up during at least 24 months after initiating cART. mtDNA genotyping was performed by Sequenom's MassARRAY platform.
  RESULTS: Patients within cluster JT and haplogroup J had a lower chance of achieving a CD4+ count ≥500 cells/mm(3) than patients within cluster HV and haplogroup H [hazard ratio (HR) = 0.68 (P = 0.058) and HR = 0.48 (P = 0.010), respectively]. The time of follow-up during which the CD4+ count was ≥500 cells/mm(3) was longer in haplogroups HV and H than in haplogroups JT and J [20 months versus 6.2 months (P = 0.029) and 20 months versus 0 months (P = 0.024), respectively]. Additionally, haplogroups HV and H had greater chances of achieving a CD4+ count ≥500 cells/mm(3) during at least 12, 36, 48 and 60 months post-cART initiation compared with patients within haplogroups JT and J. Patients within haplogroup T only had a lesser chance of achieving a CD4+ count ≥500 cells/mm(3) during at least 48 months and 60 months post-cART initiation.
  CONCLUSION: European mitochondrial haplogroups might influence CD4+ recovery in HIV-infected patients following initiation with cART. Haplogroups J and T appear to be associated with a worse profile of CD4+ recovery, whereas haplogroup H was associated with a better CD4+ reconstitution.
  

  PMID: 23749950 [PubMed - in process]

• Mitochondrial haplogroups are associated with clinical pattern of AIDS progression in HIV-infected patients. -

  Related Articles

  Mitochondrial haplogroups are associated with clinical pattern of AIDS progression in HIV-infected patients.

  J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):178-83

  Authors: Guzmán-Fulgencio M, Jiménez JL, García-Álvarez M, Bellón JM, Fernández-Rodriguez A, Campos Y, Rodríguez C, González-Garcia J, Riera M, Viciana P, Muñoz-Fernández MÁ, Resino S

  Abstract
  We performed a cross-sectional study in 469 HIV-infected patients, whose mitochondrial haplogroups were genotyped to study their association with the clinical pattern of AIDS progression. The chance of not having an AIDS progression was 1.45 [95% of confidence interval (CI) = 1.02 to 2.05, P = 0.035) times greater in patients with cluster HV and 1.51 (95% CI = 1.06 to 2.18, P = 0.021) times greater in patients with haplogroup H. However, we only found significant values for haplogroup H (odds ratio = 1.52, 95% CI = 1.01 to 2.32, P = 0.049) in an ordinal logistic regression adjusted by gender, age at HIV infection, intravenous drug users, and hepatitis C virus infection. These data suggest that mitochondrial haplogroups might play a significant role in AIDS progression.
  

  PMID: 23666137 [PubMed - indexed for MEDLINE]

• IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients. -

  Related Articles

  IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients.

  J Viral Hepat. 2013 May;20(5):358-66

  Authors: Jiménez-Sousa MA, Berenguer J, Rallón N, Guzmán-Fulgencio M, López JC, Soriano V, Fernández-Rodríguez A, Cosín J, Restrepo C, García-Álvarez M, Miralles P, Benito JM, Resino S

  Abstract
  Due to the poor rate of response to hepatitis C virus (HCV) with pegylated interferon and ribavirin treatment in HCV/HIV coinfected patients, key factors for predicting failure would be useful. We performed a retrospective study on 291 patients on HCV treatment, who had early virological response (EVR) data. IL28B and IL28RA polymorphisms were performed using the GoldenGate(®) assay. Unfavourable genotypes at IL28B (rs12980275 AG/GG and rs8099917 GT/GG) and an unfavourable allele at IL28RA (rs10903035 G) were associated with early treatment failure. However, only the rs12980275 AG/GG genotype and rs10903035 G allele remained independently associated with early failure in the overall population (OR = 4.15 (95% CI = 1.64-10.54) and OR = 2.00 (95% CI = 1.19-3.36), respectively) as well as in GT1/4 patients (OR = 5.07 (95% CI = 1.81-14.22) and OR = 2.03 (95% CI = 1.13-3.66), respectively). Next, a decision tree showed early treatment failure increased from 37.1% to 65.5% when the unfavourable rs12980275 AG/GG and rs10903035 AG/GG genotypes and HCV-RNA≥ 500.000 IU/mL were taken into account in GT1/4 patients. In contrast, the failure rate decreased from 37.1% to 11.9% when the favourable rs12980275 AA and rs10903035 AA genotypes were detected. The percentage of patients correctly classified was 78.4%, and AUROC was 0.802 ± 0.028. Regarding GT3 patients, the presence of the GCGCA haplotype (all unfavourable alleles) was associated with early treatment failure, while no association was observed for the IL28B polymorphisms. In conclusion, the IL28RA polymorphism was associated with early treatment failure independently of the IL28B SNPs. The combination of IL28B and IL28RA polymorphisms might be a valuable tool for predicting early treatment failure before starting HCV treatment.
  

  PMID: 23565619 [PubMed - indexed for MEDLINE]

• Rate of candidiasis among HIV-infected children in Spain in the era of highly active antiretroviral therapy (1997-2008). -

  Related Articles

  Rate of candidiasis among HIV-infected children in Spain in the era of highly active antiretroviral therapy (1997-2008).

  BMC Infect Dis. 2013;13:115

  Authors: Álvaro-Meca A, Jensen J, Micheloud D, Díaz A, Gurbindo D, Resino S

  Abstract
  BACKGROUND: Candidiasis is the most common opportunistic infection seen in human immunodeficiency virus (HIV)-infected individuals. The aim of our study was to estimate the candidiasis rate and evaluate its trend in HIV-infected children in Spain during the era of highly active antiretroviral therapy (HAART) compared to HIV-uninfected children.
  METHODS: We carried out a retrospective study. Data were obtained from the records of the Minimum Basic Data Set from hospitals in Spain. All HIV-infected children were under 17 years of age, and a group of HIV-uninfected children with hospital admissions matching the study group by gender and age were randomly selected. The follow-up period (1997-2008) was divided into three calendar periods: a) From 1997 to 1999 for early-period HAART; b) from 2000 to 2002 for mid-period HAART; and c) from 2003 to 2008 for late-period HAART.
  RESULTS: Among children with hospital admissions, HIV-infected children had much higher values than HIV-uninfected children during each of the three calendar periods for overall candidiasis rates (150.0 versus 6.1 events per 1,000 child hospital admissions/year (p < 0.001), 90.3 versus 3.1 (p < 0.001), and 79.3 versus 10.7 (p < 0.001), respectively) and for non-invasive Candida mycosis (ICM) rates (118.5 versus 3.8 (p < 0.001), 85.3 versus 2.3 (p < 0.001), and 80.6 versus 6.0 (p < 0.001), respectively). In addition, HIV-infected children also had higher values of ICM rates than HIV-uninfected children, except during the last calendar period when no significant difference was found (32.4 versus 1.2 (p < 0.001), 11.6 versus 0.4 (p < 0.001), and 4.6 versus 2.3 (p = 0.387), respectively). For all children living with HIV/AIDS, the overall candidiasis rate (events per 1,000 HIV-infected children/year) decreased from 1997-1999 to 2000-2002 (18.8 to 10.6; p < 0.001) and from 2000-2002 to 2003-2008 (10.6 to 5.7; p = 0.060). Within each category of candidiasis, both non-ICM and ICM rates experienced significant decreases from 1997-1999 to 2003-2008 (15.9 to 5.7 (p < 0.001) and 4.1 to 0.3 (p < 0.001), respectively).
  CONCLUSIONS: Although the candidiasis rate still remains higher than in the general population (from 1997 to 2008), candidiasis diagnoses have decreased among HIV-infected children throughout the HAART era, and it has ceased to be a major health problem among children with HIV infection.
  

  PMID: 23510319 [PubMed - in process]

• Comment on: 'interleukin-28 polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis'. -

  Related Articles

  Comment on: 'interleukin-28 polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis'.

  Gene. 2013 Jun 10;522(1):121

  Authors: Fernández-Rodríguez A, Jiménez-Sousa MÁ, Resino S

  PMID: 23506831 [PubMed - indexed for MEDLINE]

• Mitochondrial haplogroups are associated with clinical pattern of AIDS progression in human immunodeficiency virus infected patients. -

  Related Articles

  Mitochondrial haplogroups are associated with clinical pattern of AIDS progression in human immunodeficiency virus infected patients.

  J Acquir Immune Defic Syndr. 2013 Feb 7;

  Authors: Guzmán-Fulgencio M, Luis Jiménez J, García-Álvarez M, María Bellón J, Fernández-Rodriguez A, Campos Y, Rodríguez C, González-Garcia J, Riera M, Viciana P, Angeles Muñoz-Fernández M, Resino S, On behalf of CoRIS and the HIV Biobank integrated in the Spanish AIDS Research Network. On behalf of LTNPs Cohort integrated in the Spanish AIDS Research Network

  Abstract
  ABSTRACT: We performed a cross-sectional study in 469 HIV-infected patients, whose mitochondrial haplogroups were genotyped to study their association with the clinical pattern of AIDS-progression. The chance of not having a AIDS-progression was 1.45 (95% of confidence interval (95%CI)=1.02-2.05); p=0.035) times greater in patients with cluster HV and 1.51 (95%CI=1.06-2.18); p=0.021) times greater in patients with haplogroup H. However, we only found significant values for haplogroup H (OR=1.52 (95%CI=1.01-2.32; p=0.049) in an ordinal logistic regression adjusted by gender, age at HIV-infection, intravenous drug users, and HCV infection. These data suggest that mitochondrial haplogroups might play a significant role in AIDS-progression.
  

  PMID: 23392456 [PubMed - as supplied by publisher]

• Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. -

  Related Articles

  Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.

  BMC Med. 2013;11:6

  Authors: Jiménez-Sousa MA, Fernández-Rodríguez A, Guzmán-Fulgencio M, García-Álvarez M, Resino S

  Abstract
  BACKGROUND: Since 2009, several studies have identified single-nucleotide polymorphisms (SNPs) near the gene encoding for interleukin (IL)-28 (IL28B) that are strongly associated with spontaneous and treatment-induced hepatitis C virus (HCV) clearance. Because this large amount of data includes some inconsistencies, we consider assessment of the global estimate for each SNP to be essential.
  METHODS: Relevant studies assessing IL28B polymorphisms associated with sustained virologic response (SVR) and spontaneous clearance (SC) were identified from a literature search of PubMed up to 9 July, 2012. Studies were eligible studies if they included patients infected with HCV or HCV/HIV, or assessed any SNP located within or near the IL28B gene, SVR data available under standard treatment, and/or SC data in patients with acute HCV infection. Pooled odds ratios were estimated by fixed or random effects models when appropriate. Variables such as HCV genotype, ethnicity, and type of co-infection were studied.
  RESULTS: Of 282 screened studies, 67 were selected for SVR and 10 for SC. In total, 20,163 patients were studied for SVR and 3,554 for SC. For SVR, we found that all SNPs showed strong associations in patients with HCV genotypes 1 and 4, whereas the pooled ORs were almost three times lower for genotypes 2 and 3 (rs12979860 and rs8099917). Regarding ethnicity, the SNP most associated with SVR was rs12979860 in white patients, whereas in East Asians it seemed to be rs8099917. The most studied SNP (rs12979860) showed similar results for patients co-infected with HCV/HIV, as for those infected with HCV only. Finally, rs12979860 and rs8099917 both appeared to be associated with SC.
  CONCLUSIONS: IL28B polymorphisms influence both the outcome of interferon treatment and the natural clearance of HCV. However we did not identify a universal predictor SNP, as the best genetic markers differed depending on patient ethnicity, genotype, and type of infection. Nevertheless, our results may be useful for more precise treatment decision-making.
  

  PMID: 23298311 [PubMed - indexed for MEDLINE]

• Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients. -

  Related Articles

  Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients.

  AIDS. 2013 Jan 14;27(2):163-73

  Authors: Fernández-Rodríguez A, Rallón N, Berenguer J, Jiménez-Sousa MA, Cosín J, Guzmán-Fulgencio M, Restrepo C, Lopez JC, García-Álvarez M, Miralles P, Soriano V, Benito JM, Resino S

  Abstract
  OBJECTIVES: To estimate the impact of interleukin 28B (IL28B) polymorphisms (rs12980275, rs8099917, rs7248668, and rs11881222) and their haplotypes on hepatitis C virus (HCV) treatment (peg-interferon-α and ribavirin) success in 324 HIV/HCV-coinfected patients. We also explore the behavior of plasma cytokine levels.
  DESIGN: Retrospective follow-up study.
  METHODS: Virologic response to HCV treatment was measured by plasma HCV viral load at different endpoints: rapid virologic response (RVR), early virologic response (EVR), end-of-treatment virologic response (ETVR) and sustained virologic response (SVR). IL28B polymorphisms were genotyped using GoldenGate assay. Finally, 13 cytokines were measured at baseline in 57 plasma samples using a multiplex immunoassay kit.
  RESULTS: IL28B polymorphisms were strongly associated to virologic responses (RVR, EVR, ETVR, and SVR), although only for HCV genotypes 1 and 4 (P < 0.05). Strong linkage disequilibrium was detected for rs12980275/rs11881222 (r = 0.94) and rs8099917/rs7248668 (r = 0.99). IL28B haplotypes showed association but no improvement on treatment outcome prediction. Thus, the genotyping of only one single-nucleotide polymorphism was enough for predicting treatment response in GT1/4 patients with favorable rs12980275 (AA) genotype, while for subjects harboring unfavorable genotypes, the inclusion of rs8099917 was useful (SVR increased from 31 to 45%). Moreover, patients with rs12980275 (AA) that achieved SVR showed reduced plasma levels of Th1 (IFN-γ), Th2 (IL-6 and IL-9), and proinflammatory (TNF-α) cytokines.
  CONCLUSION: The presence of IL28B polymorphisms was significantly associated with HCV clearance during and after HCV therapy. The evaluated cytokine profile was much more favorable in patients with rs12980275 (AA) who achieved SVR.
  

  PMID: 23135173 [PubMed - indexed for MEDLINE]

• IL28B polymorphisms are associated with severity of liver disease in human immunodeficiency virus (HIV) patients coinfected with hepatitis C virus. -

  Related Articles

  IL28B polymorphisms are associated with severity of liver disease in human immunodeficiency virus (HIV) patients coinfected with hepatitis C virus.

  J Infect. 2013 Feb;66(2):170-8

  Authors: Guzmán-Fulgencio M, Berenguer J, García-Álvarez M, Fernández-Rodríguez A, Jiménez-Sousa MA, Alvarez E, Micheloud D, López JC, Miralles P, Cosín J, Catalán P, Resino S

  Abstract
  OBJECTIVE: To evaluate the association of IL28B polymorphisms and severity of liver disease among human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfected patients.
  METHODS: We carried out a cross-sectional study on 223 patients. Liver biopsies were evaluated according to Metavir score. IL28B polymorphisms (rs12980275, rs8099917, rs7248668, and rs11881222) were genotyped using GoldenGate(®) assay.
  RESULTS: IL28B polymorphisms were in strong linkage disequilibrium, especially the couples rs12980275/rs11881222 and rs8099917/rs7248668. For all patients, the rs12980275 A allele increased the odds for significant fibrosis (F ≥ 2) odds ratio (OR) = 1.68; p = 0.018) and more rapid fibrosis progression (FPR ≥ 0.075 fibrosis units/year) (OR = 1.64; p = 0.035), and decreased the odds for liver steatosis (OR = 0.61; p = 0.046). Furthermore, the rs8099917 T allele increased the odds for F ≥ 2 (OR = 1.93; p = 0.020), FPR ≥ 0.075 (OR = 2.08; p = 0.021), and elevated ALT (≥80 IU/l) (OR = 1.78; p = 0.048). For HCV-genotype 1 patients, rs12980275 A and rs8099917 T alleles decreased the odds for liver steatosis (OR = 0.22; p < 0.001 and OR = 0.39; p = 0.048; respectively). For HCV-genotype 3 patients, the rs12980275 A allele increased the odds for F ≥ 2 ((OR = 6.30; p = 0.012), FPR ≥ 0.075 (OR = 6.40; p = 0.025), and elevated ALT (OR = 4.12; p = 0.037); and the rs8099917 T allele also increased the odds for F ≥ 2 (OR = 7.56; p = 0.027), FPR ≥ 0.075 (OR = 50.8; p = 0.012), and elevated ALT (OR = 5.39; p = 0.043). However, we did not find significant trends in patients infected with HCV-genotype 4.
  CONCLUSION: The major alleles of IL28B (rs12980275 A, rs11881222 A, rs8099917 T, and rs7248668 G) are associated with increased odds of liver disease severity in HIV patients infected with HCV-genotype 3. In contrast, HCV-genotype 1 patients carrying the major alleles of IL28B polymorphisms had lower odds for liver steatosis.
  

  PMID: 23103287 [PubMed - indexed for MEDLINE]

• Association of torque teno virus (TTV) and torque teno mini virus (TTMV) with liver disease among patients coinfected with human immunodeficiency virus and hepatitis C virus. -

  Related Articles

  Association of torque teno virus (TTV) and torque teno mini virus (TTMV) with liver disease among patients coinfected with human immunodeficiency virus and hepatitis C virus.

  Eur J Clin Microbiol Infect Dis. 2013 Feb;32(2):289-97

  Authors: García-Álvarez M, Berenguer J, Alvarez E, Guzmán-Fulgencio M, Cosín J, Miralles P, Catalán P, López JC, Rodríguez JM, Micheloud D, Muñoz-Fernández MA, Resino S

  Abstract
  Torque teno virus (TTV) and torque teno mini virus (TTMV) have been potentially related to liver diseases. The aim of the study was to quantify TTV and TTMV in human immunodeficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients to study the relationship between the TTV and TTMV viral loads and the severity of liver disease. We carried out a cross-sectional study in 245 patients coinfected with HIV and HCV (HIV/HCV-group), 114 patients monoinfected with HIV (HIV-group), and 100 healthy blood donors (Control-group). Plasma samples were tested for TTV and TTMV by quantitative real-time polymerase chain reaction (PCR). The prevalences of TTV and TTMV infections in the HIV/HCV-group and the HIV-group were significantly higher than the Control-group (p < 0.05). Furthermore, TTV and TTMV coinfections were found in 92.2 % (226/245) in the HIV/HCV-group, 84.2 % (96/114) in the HIV-group, and 63 % (63/100 %) in the Control-group (p ≤ 0.05). HIV/HCV-coinfected patients with HIV viral load ≥50 copies/mL and patients with severe activity grade had the highest viral loads of TTV and TTMV (p ≤ 0.05). HIV/HCV-coinfected patients with high TTV load (>2.78 log copies/μL) had increased odds of having advanced fibrosis or severe necroinflammatory activity grade in the liver biopsy. Moreover, HIV/HCV-coinfected patients with high TTMV load (>1.88 log copies/μL) had decreased odds of having no/minimal fibrosis and no/mild activity grade, and increased odds of having a high fibrosis progression rate. In conclusion, TTV and TTMV might play a role in the development of liver disease in immunodeficiency patients, such as the patients coinfected with HIV and HCV.
  

  PMID: 22983402 [PubMed - indexed for MEDLINE]

• Bacterial DNA translocation and liver disease severity among HIV-infected patients with chronic hepatitis C. -

  Related Articles

  Bacterial DNA translocation and liver disease severity among HIV-infected patients with chronic hepatitis C.

  J Acquir Immune Defic Syndr. 2012 Dec 15;61(5):552-6

  Authors: García-Álvarez M, Berenguer J, Guzman-Fulgencio M, Alvarez E, Cosín J, Micheloud D, Jimenez-Sousa MA, Fernández-Rodríguez A, Aldámiz-Echevarría T, Carrero A, Miralles P, Resino S

  Abstract
  We carried out a cross-sectional study to explore whether bacterial 16S ribosomal DNA (bactDNA) shows association with severity of liver disease among human immunodeficiency virus/hepatitis C virus coinfected patients. Patients with advanced fibrosis (F3/F4), moderate activity grade (A2/A3), and high fibrosis progression rate (FPR > 0.15) had higher values of plasma bactDNA levels than did patients without these markers of liver disease (P < 0.05). The chance of having a fibrosis stage or activity grade increased was 1.20 [95% confidence interval (CI) = 1.0 to 1.44, P = 0.045] and 1.22 (95% CI = 1.1 to 1.45, P = 0.029) times greater for every 100 copies per microliter of plasma bactDNA. Likewise, the odds of having values of FPR > 0.15 was 1.18 (95% CI = 0.98 to 1.42, P = 0.089). In addition, patients with high bactDNA levels (≥175 copies per microliter) had the highest odds of having high values of Metavir score and FPR (P < 0.05). Our data show that bacterial translocation is associated with severe liver disease among human immunodeficiency virus-infected patients with chronic hepatitis C.
  

  PMID: 22932319 [PubMed - indexed for MEDLINE]